Resumed H.C. Wainwright
Reiterated H.C. Wainwright
$37 → $30
Initiated RBC Capital Mkts
Perform → Outperform
Initiated Chardan Capital Markets
Initiated Robert W. Baird
Initiated Evercore ISI
Initiated H.C. Wainwright
Initiated Canaccord Genuity
Initiated B. Riley FBR
Jan-13-20 02:30PM American City Business Journals
Jan-10-20 02:20PM American City Business Journals
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
SEC Form 4
Kelly Timothy P See Remarks. Mar 01 Option Exercise 4.76 4,000 19,052 6,232 Mar 03 04:05 PM Smith W Bradford CFO & Treasurer Feb 08 Option Exercise 0.64 13,500 8,640 13,500 Feb 09 04:22 PM Smith W Bradford CFO & Treasurer Feb 08 Sale 14.25 13,500 192,425 0 Feb 09 04:22 PM Kelly Timothy P See Remarks Feb 02 Option Exercise 6.63 500 3,316 500 Feb 05 06:31 AM Kelly Timothy P See Remarks Feb 02 Sale 13.00 500 6,500 0 Feb 05 06:31 AM Kelly Timothy P See Remarks Feb 01 Option Exercise 4.76 4,000 19,052 4,000 Feb 03 04:05 PM Kelly Timothy P See Remarks Feb 01 Sale 12.37 4,000 49,460 0 Feb 03 04:05 PM Kelly Timothy P See Remarks Jan 12 Option Exercise 6.63 500 3,316 500 Jan 14 04:05 PM Kelly Timothy P See Remarks Jan 12 Sale 13.00 500 6,500 0 Jan 14 04:05 PM Seymour Albert Chief Scientific Officer Jan 07 Sale 12.05 5,103 61,469 129,017 Jan 08 04:05 PM Seymour Albert Chief Scientific Officer Jan 06 Sale 12.06 9,897 119,395 134,120 Jan 08 04:05 PM Seymour Albert Chief Scientific Officer Jan 05 Sale 11.44 10,000 114,422 144,017 Jan 07 04:05 PM Kelly Timothy P See Remarks Jan 04 Option Exercise 4.76 4,000 19,052 4,000 Jan 06 04:05 PM Kelly Timothy P See Remarks Jan 04 Sale 11.50 4,000 45,983 0 Jan 06 04:05 PM PARMAR KUSH Director Dec 22 Sale 12.82 500,000 6,410,000 181,435 Dec 28 09:37 PM 5AM Ventures IV, L.P. 10% Owner Dec 22 Sale 12.82 500,000 6,410,000 181,435 Dec 28 09:35 PM PARMAR KUSH Director Dec 14 Sale 12.25 500,000 6,125,915 201,435 Dec 16 07:25 PM 5AM Ventures IV, L.P. 10% Owner Dec 14 Sale 12.25 500,000 6,125,915 201,435 Dec 16 07:15 PM Kelly Timothy P See Remarks Mar 17 Sale 13.01 1,315 17,109 0 Mar 18 05:32 PM
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite